ALK and non-small cell lung carcinoma: In parallel, positive DFS results from the ALINA trial led to the approval of alectinib by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the adjuvant setting of patients with stage IB (≥4 cm)–IIIA (TNM 7) resected NSCLC with ALK gene rearrangements [30].